Skip to: Content
Skip to: Site Navigation
Skip to: Search

July 25, 2008 7:54:23 AM CDT

Learn about Newser Points »

Stories related to: Merck

Stories

Stories 1 - 20 of 21

<< Prev 1 2 Next >>
  • July 2008

    • Pharma, Tech Kill Early Gains

      newser  |  MarketWatch  |  Jul 21, 08 3:40 PM CDT

      Pharma, Tech Kill Early Gains

      The markets failed to hold on to early-session gains today as oil rose above $131 per barrel and the overall economic outlook remained downcast, MarketWatch reports. The Dow lost 29.23 points to close at 11,467.34, the Nasdaq fell 3.25 to 2,279.53, and the S&P 500 dropped just 0.68, settling at 1,260.00. More »

  • May 2008
  • April 2008

    • Investors Cagey, Stocks Mixed as Fed Meets

      newser  |  Wall Street Journal  |  Apr 29, 08 3:36 PM CDT

      Investors Cagey, Stocks Mixed as Fed Meets

      Stocks ended mixed but mostly down today as cautious investors digested bad economic news while the Fed met, presumably to discuss further rate cuts. "In many ways, the economy seems fundamentally weaker now" than during the last official recession in 2001, an economist told the Wall Street Journal . The Dow ended down 39.81 at 12,831.94, the Nasdaq up 1.70 at 2,426.10, and the S&P 500 down 5.43 at 1,390.94. More »

      Tags

      stock market  • Merck

    • Serious Side Effects Linked to Avandia, Fosamax

      newser  |  Reuters  |  Apr 29, 08 2:57 AM CDT

      Serious Side Effects Linked to Avandia, Fosamax

      Two new studies have linked the popular prescription drugs Fosamax and Avandia to serious side effects, Reuters reports. Fosamax, prescribed for osteoporosis, has been tied to a type of abnormal heartbeat that can cause dizziness and fatigue. Another study links Avandia, used to treat diabetes, to a double or even triple risk of broken limbs after long-term use. More »

      Tags

      diabetes  • Merck  • GlaxoSmithKline  • Avandia  • osteoporosis  • Food and Drug Administration  • Fosamax

    • Merck Used Ghostwriters to Draft Rosy Vioxx Studies

      newser  |  Wall Street Journal  |  Apr 15, 08 7:51 PM CDT

      Merck Used Ghostwriters to Draft Rosy Vioxx Studies

      Merck used its own ghostwriters to draft articles minimizing risks of its drug Vioxx, then found medical researchers to lend their names to the research, the Wall Street Journal reports. Merck, which pulled the painkiller from shelves four years ago over heart-attack risks, rejects the claims as "misleading." They appear in tomorrow's edition of the Journal of the American Medical Association . More »

      Tags

      ethics  • pharmaceutical companies  • Merck  • Vioxx  • medical studies  • JAMA

    • Doc: Merck Fudged Minutes of Meeting

      newser  |  Bloomberg  |  Apr 12, 08 9:33 AM CDT

      Doc: Merck Fudged Minutes of Meeting

      Merck's "minutes" of a meeting of heart doctors discussing cholesterol drug Vytorin were created a month after the meeting and distorted the viewpoints of the experts, one panel member changes. The drug company submitted the document to congressional investigators probing its two-year delay in releasing a report saying the drug didn't work any better than a much cheaper generic one, Bloomberg reports. More »

    • Slow Day Sees Modest Losses

      newser  |  Wall Street Journal  |  Apr 2, 08 3:48 PM CDT

      Slow Day Sees Modest Losses

      The markets slid into negative territory after Ben Bernanke's Congressional testimony on the state of the economy today, but trading was generally low-key. "Flat is good," an economist told the Wall Street Journal . "People are getting their nerve back." The Dow ended down 45.44 at 12,608.92, the Nasdaq down 1.35 at 2,361.40, and the S&P 500 down 2.65 at 1,367.53. More »

      Tags

      stock market  • Ben Bernanke  • Merck  • International Monetary Fund  • IMF  • Best Buy

    • Firms Hid Bad News on Heart Drugs 2 Years: Doc

      newser  |  New York Times  |  Apr 1, 08 10:49 AM CDT

      Firms Hid Bad News on Heart Drugs 2 Years: Doc

      A scientist hired by two drug companies to conduct trials of cholesterol-lowering drugs accused the firms of deliberately delaying release of the results, the New York Times reports. The results for the Vytorin and Zetia trials—which showed the drugs don't work to reduce plaque in arteries—were not released until almost two years after the medical trials wrapped up.  More »

  • March 2008

    • 2 Top Cholesterol Drugs, Vytorin and Zetia, Don't Work

      newser  |  New York Times  |  Mar 31, 08 3:55 AM CDT

      2 Top Cholesterol Drugs, Vytorin and Zetia, Don't Work

      Two top-selling cholesterol drugs  proved in a recent study to be largely ineffective in slowing the clogging of arteries, a panel of cardiologists said yesterday. Doctors should only prescribe Vytorin and Zetia if other medications don't work, and should rely instead on statins such as Lipitor and Zocor, they said. “The strongest recommendation we can make is to go back to statins,” said one of the doctors. “They work.” More »

    • FDA Probes Suicide Link to Asthma Drug

      newser  |  USA Today  |  Mar 28, 08 7:09 AM CDT

      FDA Probes Suicide Link to Asthma Drug

      The FDA has opened an investigation of anecdotal links between the popular asthma and allergy drug Singulair and suicidal thoughts. In the past year, manufacturer Merck has added warnings of several possible side effects of  the pill related to the nervous system, including anxiety, depression, tremors, and suicidal thinking. The FDA says its review of the drug, which had sales of more than $4.3 billion last year, may take up to nine months. More »

      Tags

      FDA  • suicide  • Merck  • asthma  • allergy  • Singulair

  • February 2008

    • Merck Will Pay $650M to End Discount Probes

      newser  |  Wall Street Journal  |  Feb 7, 08 3:59 PM CST

      Merck Will Pay $650M to End Discount Probes

      Drug company Merck will dish out $650 million to resolve lawsuits and probes into marketing schemes, the Wall Street Journal reports. Central to the investigations is the company’s “nominal pricing,” which slashed some drug prices by 90% for hospitals but hid the discounts from Medicaid, even though federal law demands that drug companies offer the government program their lowest prices. More »

      Tags

      lawsuit  • drugs  • pharmaceutical companies  • hospitals  • Merck  • Vioxx  • probe  • Zocor

  • January 2008
  • December 2007

    • Merck Recalls 1M Doses of Vaccine for Kids

      newser  |  Associated Press  |  Dec 12, 07 7:14 PM CST

      Merck Recalls 1M Doses of Vaccine for Kids

      Merck is recalling almost a million doses of a childhood vaccine after it found evidence of contamination at one of its factories, the AP reports. The pharmaceutical giant says no children have been harmed after taking Hib, which prevents meningitis and pneumonia, but the company is recalling its 10 lots and two lots of a combination vaccine for both Hib and hepatitis B. More »

      Tags

      Merck  • vaccine  • pharmaceutical industry  • Vioxx  • pneumonia  • meningitis  • hepatitis B

  • November 2007

    • Merck to Settle Suits for $4.85B

      newser  |  New York Times  |  Nov 9, 07 5:19 AM CST

      Merck to Settle Suits for $4.85B

      Merck has agreed to shell out $4.85 billion to settle 27,000 Vioxx lawsuits brought by plaintiffs who argued that the pain medication damaged health and caused deaths. The agreement, one of the largest in history, must still be approved by 85% of the plaintiffs, but it's likely to go through, reports the New York Times. More »

      Tags

      settlement  • civil lawsuits  • Merck  • painkiller  • Vioxx  • drug safety

    • Cold Virus Foiled AIDS Vaccine

      newser  |  Washington Post  |  Nov 8, 07 1:08 PM CST

      Cold Virus Foiled AIDS Vaccine

      A promising AIDS vaccine that failed in trials—actually increasing rather than reducing risk of infection—turned out to be ineffective in people who had immunity to a common cold virus, developers reported yesterday. The Merck vaccine contained an altered version of that virus, and study subjects with existing immunities to it saw increased risk of contracting HIV, the the Washington Post reports. More »

      Tags

      AIDS  • HIV  • Merck  • AIDS vaccine

  • October 2007

    • Experimental AIDS Vaccine May Increase HIV Risk

      newser  |  Wired  |  Oct 25, 07 6:38 PM CDT

      Experimental AIDS Vaccine May Increase HIV Risk

      A once-promising AIDS vaccine being developed by Merck may actually increase the risk of contracting HIV, the Washington Post reports. In South Africa, 19 people who received the vaccine in a trial contracted the virus, as opposed to 11 who received a placebo. South  African researchers have begun warning hundreds of participants of the findings. More »

      Tags

      AIDS  • HIV  • Merck

  • May 2007

Stories 1 - 20 of 21

<< Prev 1 2 Next >>

Today's Most Popular

Loading...

What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »